Navigation Links
Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at

Dallas, Texas (PRWEB) June 06, 2013

Monoclonal Antibodies Partnering Terms & Agreements are intended to provide the reader with an in-depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

Monoclonal Antibodies Partnering Terms & Agreements ( includes:

  •     Trends in monoclonal antibodies dealmaking in the Biopharma industry since 2007
  •     Analysis of monoclonal antibodies deal structure
  •     Access to headline, upfront, milestone and royalty data
  •     Access to over 700 monoclonal antibodies deal records
  •     The leading monoclonal antibodies deals by value since 2007
  •     Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2007

In Monoclonal Antibodies Partnering Terms & Agreements, the available deals are listed by:

  •     Company A-Z
  •     Headline value
  •     Stage of development at signing
  •     Deal component type
  •     Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Monoclonal Antibodies Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals' terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2007 including financial terms where available including over 700 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  •     What is actually granted by the agreement to the partner company?
  •     What exclusivity is granted?
  •     What are the precise rights granted or optioned?
  •     What is the payment structure for the deal?
  •     How are sales and payments audited?
  •     What is the deal term?
  •     How are the key terms of the agreement defined?
  •     How are IPRs handled and owned?
  •     Who is responsible for commercialization?
  •     Who is responsible for development, supply, and manufacture?
  •     How is confidentiality and publication managed?
  •     How are disputes to be resolved?
  •     Under what conditions can the deal be terminated?
  •     What happens when there is a change of ownership?
  •     What sublicensing and subcontracting provisions have been agreed?
  •     Which boilerplate clauses does the company insist upon?
  •     Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  •     Which jurisdiction does the company insist upon for agreement law?

Buy a copy of report @

Monoclonal Antibodies Partnering Terms & Agreements provides the reader with the following key benefits:

  •     In-depth understanding of monoclonal antibodies deal trends since 2007
  •     Access to headline, upfront, milestone and royalty data
  •     Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
  •     Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world’s biopharma companies
  •     Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  •     Understand the key deal terms companies have agreed in previous deals        
  •     Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Explore more reports on Pharmaceuticals Market @

About US: is an online market research reports ( library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Monoclonal Antibodies Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
2. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
3. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
4. Research reveals how antibodies neutralize mosquito-borne virus
5. Genetically modified tobacco plants produce antibodies to treat rabies
6. NIH scientists identify protective role for antibodies in Ebola vaccine study
7. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
8. Autoantibodies damage blood vessels in the brain
9. Antibodies for new rotavirus vaccines
10. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
11. Antibodies from rabbits reduce risks associated with
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: